First Named Inventor

P31853C1

Buckingham et al.

nonprovisional applications under 37 CFR 1.53(b))

"EXPRESS MAIL CERTIFICATE"

PRESS MAIL" MAILING LABEL NUMBER EL808220401US DATE OF DEPOSIT: AUGST 24, 2001

		<u> </u>	
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		7. 🛚	The Title of the Invention: TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND DIGUANIDE
1. 🛛	The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570 General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) (Submit an original, and a duplicate for fee processing)	8.	Nucleotide and/or Amino Acid Sequence Submission a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies d. Use the identical computer-readable form filed in Application No, filed as the computer-readable form for the instant application. (37 CFR 1.821(e))
2. X	The total fee is calculated as shown below: Basic Filing fee \$710.00 Total Claims $22 - 20 = 2 \times 18$ \$36.00 Independent Claims $4 - 3 = 1 \times 80$ \$80.00 Multiple Dependent Claim present. \$270	9.	a. ☐ Information Disclosure Statement (IDS) b. ☐ PTO-1449 c. ☐ Copies of all IDS Citations
	TOTAL FILING FEE \$826.00	10.	Assignment Papers (cover sheet & document(s))
	Cancel in this application original claims _to _of the prior application before calculating the filing fee.	11. 🛛	Prior Application is Assigned to: SmithKline Beecham p.l.c. (for continuation/divisional with Box 17a completed)
3a. ⊠	Charge <u>\$826.00</u> to the above indicated Deposit Account. Specification excluding Drawings [Total Pages] 13	12.	Preliminary Amendment [Total Pages] 5
3ь. 🛛	Abstract on a separate sheet [Total Pages] 1	10 57	D. C. D. Control (MDED 502)
a u	Drawing(s) (35 USC 113) [Total Sheets]	13.	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
	Declaration and Power of Attorney [Total Pages] 2 a. ☐ Newly executed (original or copy) b. ☐ Copy from a prior application (37 CFR 1.63(d))	14.	Certified Copy of Priority Document(s) (if foreign priority is claimed)
To the second se	(for continuation/divisional with Box 17a completed) c. Unsigned Declaration [Note Box 6 below] i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	15. 🖾	Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. 09/446,039 filed December 15, 1999. A PTO-1449 listing the references is enclosed. Other:
6. Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.			
17.	17. Priority Information, check appropriate box and supply the requisite information		
a.	Continuation Divisional Continuation-in-part (CIP)		
b.	Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. filed .		
c.	NA DI La Cartina ha inserting hefore the first line the centence: (37 CFR 1.78)		
C.	OX A VOCATION INTO		Respectfully Submitted,
Address	P.O. Box 1539	Signatu Name	
Telepho	King of Prussia, PA 19406-0939 (610) 270-5018 Fax (610) 270-5073	Registr No.	